A carregar...
Inhibition of Bupropion Metabolism by Selegiline: Mechanism-Based Inactivation of Human CYP2B6 and Characterization of Glutathione and Peptide Adducts
Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6. The effect of selegiline on the enzymatic activity of human cytochrome CYP2B6...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3500550/ https://ncbi.nlm.nih.gov/pubmed/22936314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.112.046979 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|